Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Network Bio launched with $50 million to build an AI platform integrating human tissue, blood biomarkers, molecular data, and longitudinal clinical outcomes across academic biobanks. The approach treats age-related disease as overlapping manifestations of shared biological dysfunction rather than isolated conditions, positioning computational models to identify transferable signals that precede multiple chronic diseases.
United Therapeutics completed enrollment of 754 patients in TETON-PPF, a phase 3 trial testing nebulized treprostinil for progressive pulmonary fibrosis. The 52-week study measures forced vital capacity decline and clinical worsening, with results expected in late 2027. This represents a potential new therapeutic option for a disease with limited treatment pathways.
Haut.AI's AI-powered skin analysis technology has expanded from 24 to approximately 4,000 O Boticário stores across Brazil, scaling a system that analyzes over 150 facial biomarkers to deliver personalized skincare assessments in 80 seconds. The pilot demonstrated an 80% increase in average skincare order value, suggesting that precise phenotypic assessment drives both product matching and consumer engagement.
Function has released a secure data connector enabling members to integrate their lab results and clinical notes with mainstream AI platforms, allowing AI systems to generate responses tailored to individual biomarker profiles rather than population averages. This approach addresses a fundamental gap in health optimization: AI guidance grounded in personal biological data rather than generalized recommendations.
OncoC4 has dosed the first patient in a Phase 1 trial of ONC-783, a T-cell engager targeting cancer-specific CD24 glycoforms in advanced solid tumors. Early data shows tolerability without severe adverse events, positioning this as a potential addition to the immunotherapy landscape for cancers with limited treatment options.
NeuroQuant PET, an FDA-cleared AI software platform, automates the quantitative analysis of PET brain scans to detect amyloid accumulation and assess cognitive decline. The tool standardizes interpretation across clinical settings by converting subjective visual assessment into objective, quantified metrics integrated directly into existing imaging workflows.
Family caregivers of dementia patients experience significant pain linked to both care recipient characteristics and caregiver-specific factors. Understanding these associations helps identify which caregivers face highest risk for physical health deterioration and where intervention may prevent compounding morbidity.
Project ECHO, a telemedicine-based learning model, improves primary care providers' knowledge, confidence, and clinical skills in geriatric and dementia care. This addresses a critical gap: most patients with cognitive decline are managed in primary care settings despite widespread practitioner skill deficits in this domain.
In aging skin, the circadian regulator BMAL1 and the mechanical-response protein YAP form a pathological partnership that amplifies chronic inflammation through enhanced activity at inflammatory gene enhancers. This mechanism reveals how age-associated changes in the skin's microenvironment disrupt normal inflammatory control, contributing to the inflammatory phenotype characteristic of advanced age.
GenBio has developed AIDO Cell, an AI system that simulates human cells across multiple biological scales—from DNA to whole-cell behavior—and predicts responses to drugs and interventions. This represents a significant advance toward computational modeling of cellular function, which could accelerate drug discovery and fundamental understanding of how perturbations propagate through biological systems.
AlzeCure Pharma licensed its NeuroRestore platform to Danish biotech QuantumCell for $12 million upfront, with the lead candidate ACD856 designed to enhance nerve cell communication across multiple neurodegenerative conditions. The transaction demonstrates a viable funding model for early-stage biotech and positions a multi-indication drug candidate for clinical advancement that individual companies cannot sustain alone.
GenBio AI's AIDO Cell integrates DNA, RNA, protein, and cellular behavior into a single computational model that retains the history of previous perturbations, enabling simulation of how sequential biological interventions accumulate over time. This stateful approach addresses a fundamental limitation in aging research: the recognition that cellular state depends on accumulated history rather than isolated snapshots.